Cisplatin and etoposide combination in the treatment of bronchogenic carcinoma

Chemioterapia. 1984 Feb;3(1):16-8.

Abstract

The authors investigated the activity of a combination of DDP 80 mg/m2 i.v. followed by VP16 50 mg/m2 on days 2-5 in bronchogenic carcinoma. Twenty-seven patients entered the study (10 small cell carcinoma, 9 squamous cell, 2 adenocarcinomas and 6 histologically undefined). Six patients evidenced partial response (22.3%); one patient (small cell) had complete remission. The toxicity of the regimen was scarce and well-tolerated by patients with an incidence of 88.8% alopecia, and 77.7% nausea and/or vomiting.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Bronchogenic / drug therapy*
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Squamous Cell / drug therapy*
  • Cisplatin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Lung Neoplasms / drug therapy*
  • Middle Aged

Substances

  • Etoposide
  • Cisplatin